Invivo preps launch for €100M fund with an emphasis on advanced therapies

Invivo is targeting €100 million ($108.7 million) for its third fund, with an eye on European early-stage biotechs with advanced therapies such as cell therapy, gene therapy and synthetic biology.

The Barcelona-based VC has helped steer some notable exits for its portfolio companies, including Genfit’s 2022 Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks